Raphael Labs

Raphael Labs was a private Irish-registered biopharmaceutical company with UK affiliates focused on prophylactic nasal spray products for respiratory viral infections. Its best-known asset was pHOXWELL, developed through subsidiary pHOXBIO, which was reported to have shown positive results in a Phase 2/3 study for prevention of SARS-CoV-2 infection in high-risk healthcare workers. The company also described a broader respiratory-virus prevention portfolio including pHOXGEN and referenced a proprietary formulation called Vita Raphael in external materials. Corporate records and business databases indicate that the Irish company entered liquidation, while its UK entities were dissolved, so the business does not appear to be active as of 2026. Raphael Labs therefore appears to be a defunct private biotech rather than an operating commercial-stage healthcare company.